# StrateGIST 3: HCP commentary report

> 84 verified statements (46 from clinicians verified by NPI or staff page) from 17 commentary sources · 9 findings · updated Oct 31, 2026

## Report

- Trial: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
- NCT ID: NCT07218926
- Registry: https://clinicaltrials.gov/study/NCT07218926
- Sponsor: GlaxoSmithKline
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: velzatinib (IDRX-42)
- Indication: metastatic and/or unresectable gastrointestinal stromal tumors after imatinib
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 529a216e8bdec1fa9c1601d9dde893b26abb09285825dd0a449bc461395c0a32

## Counts

- HCP commentary sources screened: 22
- Sources cited by verified statements: 18
- Verified statements: 84
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 46
- Findings: 9
- Named people in screened sources (unnamed speakers and accounts not counted): 6
- Voices cited: 6
- Cited voices identity-verified: 5
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

StrateGIST 3 asks whether velzatinib improves disease control and safety versus sunitinib after imatinib in metastatic or unresectable GIST. Commentary comes from X and LinkedIn posts and podcasts featuring medical oncologists and a hematology–oncology physician. Discussion centers on referral timing and whether randomized evidence will support early velzatinib enthusiasm. For mixed resistance, one medical oncologist’s conditional preference for an accessible combination over trial participation raises a competing treatment-choice question.

## Open Medical Affairs question

How can Medical Affairs distinguish molecular rationale, conditional access preferences and referral advice from demonstrated comparative benefit while preserving the tolerability and eligibility exceptions?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. For mixed resistance, one speaker prefers an accessible combination over the randomized trial
- F2. Referral timing is portrayed as a treatment decision that can close access
- F3. Molecular profiling is strongly supported, but a detected mutation is not a deterministic treatment rule
- F4. Broad inhibition: an unseen-clone rationale, not demonstrated eradication or cure
- F5. Velzatinib enthusiasm rests on early activity and tolerability, pending randomized confirmation
- F6. Sunitinib's practical burden is part of the choice, not just an efficacy benchmark
- F7. The post-imatinib decision also includes confirming progression and considering local treatment
- F8. Additional second-line options remain a conditional forecast
- F9. Regional coordination, full eligibility review and patient preparation are central to participation

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 6 | 3 | 2 | 1 | recorded | 3 |
| F2 | 15 | 11 | 8 | 2 | none recorded | 3 |
| F3 | 12 | 9 | 2 | 3 | recorded | 4 |
| F4 | 14 | 9 | 3 | 4 | recorded | 3 |
| F5 | 6 | 6 | 5 | 3 | none recorded | 3 |
| F6 | 9 | 5 | 2 | 2 | none recorded | 4 |
| F7 | 6 | 6 | 2 | 2 | none recorded | 4 |
| F8 | 3 | 3 | 2 | 2 | none recorded | 3 |
| F9 | 20 | 14 | 10 | 4 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 5 | 0 | 0 | 0 | 1 | 6 | 0 | 1 podcast or video, 1 registry | yes |
| F2 | 11 | 0 | 2 | 0 | 2 | 18 | 0 | 7 posts and articles, 1 registry | yes |
| F3 | 5 | 1 | 3 | 2 | 1 | 13 | 0 | 2 podcasts and video | yes |
| F4 | 8 | 1 | 1 | 2 | 2 | 14 | 0 | 1 post or article, 2 podcasts and video | yes |
| F5 | 4 | 0 | 1 | 0 | 1 | 7 | 1 | 4 posts and articles, 1 podcast or video | yes |
| F6 | 5 | 0 | 1 | 0 | 3 | 11 | 0 | 2 podcasts and video | yes |
| F7 | 6 | 0 | 0 | 0 | 0 | 7 | 0 | 2 podcasts and video | yes |
| F8 | 3 | 0 | 0 | 0 | 0 | 4 | 0 | 2 podcasts and video | yes |
| F9 | 10 | 0 | 2 | 0 | 8 | 23 | 0 | 8 posts and articles, 1 podcast or video, 1 registry | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS): F9 (1 shared claims)
- Secondary endpoints: no finding draws on it directly
- Population and setting: F2 (4 shared claims), F9 (9 shared claims)
- The comparison: F1 (2 shared claims), F2 (1 shared claims), F3 (4 shared claims), F4 (1 shared claims), F5 (3 shared claims), F6 (1 shared claims), F9 (5 shared claims)
- Safety and tolerability: F1 (1 shared claims), F4 (1 shared claims), F5 (3 shared claims), F6 (6 shared claims)
- Design and conduct: F1 (1 shared claims), F5 (2 shared claims), F9 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. For mixed resistance, one speaker prefers an accessible combination over the randomized trial

A medical oncologist in a podcast discussion addressed the choice between StrateGIST 3 participation and an expanded-access combination for GIST with mixed resistance.

This is the podcast publication date; it does not establish when the discussion took place.

Source: podcast, 2026-03-20.

### F5. Velzatinib enthusiasm rests on early activity and tolerability, pending randomized confirmation

A hematology–oncology physician’s podcast discussion addressed questions about early velzatinib activity and tolerability, and the randomized comparison with sunitinib.

This is the podcast publication date; it does not establish when the discussion took place.

Source: podcast, 2026-07-27.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 84 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 18 | Counts free |
| Speaker attribution for cited voices | 6 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) | discussed | 1 | 1 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 11 | 7 |
| The comparison | discussed | 17 | 10 |
| Safety and tolerability | discussed | 9 | 4 |
| Design and conduct | discussed | 5 | 5 |
| Pre-switch referral, imatinib continuity and the risk of losing eligibility | discussed | 15 | 7 |
| Resistance profiling, mutation-guided selection and predictive uncertainty | discussed | 16 | 2 |
| Broad mutation coverage, competing regimens and resistance research | discussed | 15 | 3 |
| Progression assessment, systemic versus local treatment and the comparator pathway | discussed | 13 | 2 |
| Regional access, local co-management and preparation for shared decisions | discussed | 16 | 9 |
| Early evidence maturity and conditional future second-line options | discussed | 10 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 15 | 11 |
| LinkedIn posts | 5 | 4 |
| Podcasts | 2 | 2 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-10-29 to 2026-10-07
- Cited window: 2026-03-20 to 2026-10-07
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
- Registry: NCT07218926 (https://clinicaltrials.gov/study/NCT07218926)
- Study IDs: 300383 · 2025-522229-37-00
- Sponsor: GlaxoSmithKline
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 450 (estimated)
- Start: 2025-12-03 (actual)
- Primary completion: 2028-05-30 (estimated)
- Primary endpoint: Progression-Free Survival (PFS) (Up to approximately 130 weeks)
- Intervention: IDRX-42 (drug)
- Intervention: Sunitinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on early-line tolerability, activity and evidence limitations informing treatment selection after imatinib.
- Not yet captured in this edition: a view on mutation coverage and combination alternatives for second-line treatment of advanced GIST.
- Not yet captured in this edition: a view on timely trial referral and continuing imatinib before switching second-line treatment.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative HCP sample. Repeated posts and reposts should not be counted as independent views or consensus.
- Some potentially relevant social posts and replies were not fully assessed, and some referral material had unresolved author attribution. Additional relevant views may be missing.
- No exact-trial results publication was identified. No separate protocol or exact IDRX-42 regulatory label was available; comparative efficacy, comparative safety and regulatory outcomes cannot be concluded from this discussion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Three speakers are each described in the source as involved in StrateGIST 3. Their favorable outreach is not treated as independent external validation.
- Several clinical statements concern other studies, exploratory subgroups, practice experience or a presented case. Their relevance is to the post-imatinib decision, not to observed StrateGIST 3 outcomes.
- The discussion of repeat molecular testing, specific combination choices and approval timing is incomplete; it should not be read as a comprehensive account of those recommendations or forecasts.
- Publication and post dates establish when material appeared, not necessarily when a session occurred, results were presented or an opinion changed.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (84 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (5 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/strategist-3-nct07218926
- Agents: POST https://www.erudio.com/api/orders with {"report": "strategist-3-nct07218926", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=strategist-3-07218926

## Cite

Erudio Health. StrateGIST 3 (NCT07218926): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/strategist-3-nct07218926

## Machine access

- JSON: https://www.erudio.com/reports/strategist-3-nct07218926.json
- Markdown: https://www.erudio.com/reports/strategist-3-nct07218926.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "strategist-3-07218926"}`